Page 55 - Pharma Sector

Crude to snuff gains from weak rupee, muted global demand to hurt exports

Tourism and hospitality, auto and aviation could see a demand crunch amid coronavirus; earnings from rupee depreciation to export-driven sectors such as IT and pharma could be limited

Europe 'panicking' over India's pharma export curbs: Industry body

India's list of restricted medicines account for 10 per cent of its total pharmaceutical exports and includes several antibiotics, as well as Paracetamol

Pharma group seeks relaxation of export restrictions for committed orders

Bhaskar explained that some of the orders for institutional supplies mandate the supply of all items committed in their contracts.

India stocks up for Coronavirus, restricts exports of 26 pharma ingredients

Coronavirus in India: The government said on Tuesday it had detected "high viral load" in six people who had been in contact with a patient who contracted the coronavirus in the capital New Delhi.

Coronavirus: Govt restricts exports of 26 active pharma drugs, formulations

India on Monday reported two new cases of the novel coronavirus, including one from the national capital. The outbreak has killed more than 3,000 people globally

Will double turnover with anti-diabetic bet, says Boehringer Ingelheim

Boehringer has expanded its field force to 570 representatives to boost their diabetes medicine sales that contributes nearly 75 per cent of the company's turnover

USFDA warnings: Concerns remain even as India fares better than US

According to the USFDA, India accounted for nearly 18 per cent of the active pharmaceutical ingredients (APIs) sourced by the US, while China accounted for 13 per cent

Coronavirus-induced lockdown in China can put the brakes on pharma funds

Money managers say domestic API manufacturers can stall impact from Chinese lockdown

TCS bags $1.5-bn contract from US drug firm Walgreens Boots Alliance

The expansion of WBA and TCS strategic partnership is based on WBA's review of its IT operating model and vendor landscape

Drugmakers slash prices to be eligible for China's bulk-buy program

Sale prices of over 100 types of commonly used drugs are on average about 17 to 18 times of their manufacturing costs, the statement said

Pharma chemical from China and Saudi Arabia faces anti-dumping duty

The company has filed an application before the directorate for investigation into the imports from these countries for imposing anti-dumping duty

USFDA classifies inspection of Lupin unit as 'Official Action Indicated'

Official Action Indicated means 'objectionable conditions were found and regulatory administrative sanctions by FDA are indicated' during inspections

20 key industrial, political and economic developments to expect in 2020

Where is the Sensex headed? will the economy turn around? what about sectors like auto, pharma, consumer goods and infra? Business Standard tells you what to expect in the new year

Centre may cap trade margins for drugs in stages; companies oppose plans

While the trade margins for branded generics are standardised by trade, the margins vary in the case of unbranded generics

Pharma sector likely to grow at 10-12% during FY19-22, outlook stable: Icra

Icra cited abating headwinds from pricing pressure in the US, stable growth for the Indian market driven by increasing healthcare spending

Stricter regulations, pricing control slow down pharma sector growth

The fifth part of the series looks at what's ailing the pharma sector

Dr Reddy's launches cancer treatment drug Bortezomib in the US market

Bortezomib is an active ingredient similar to that of the once blockbuster cancer treatment Velcade of Millennium Pharmaceuticals

Siddharth Mittal succeeds Arun Chandavarkar as CEO, Joint MD of Biocon

Bengaluru-headquartered biopharmaceuticals company Biocon Ltd on Tuesday said Siddharth Mittal has taken over as its chief executive officer and joint managing director. "Siddharth Mittal has taken over as Chief Executive Officer & Joint Managing Director of the company starting December 1, 2019," the company said in a BSE filing. Mittal has been serving as Chief Financial Officer (CFO) of Biocon since August 2014, the filing said. Mittal takes over from Arun Chandavarkar who retired as chief executive and joint MD of the company on November 30. "I am very pleased to welcome Siddharth as CEO & Joint MD of Biocon," Biocon CMD Kiran Mazumdar-Shaw said.

Indian pharma cos with bigger US presence face more FDA scrutiny: Analysts

Big entities such as Aurobindo and Dr Reddy's have been currently filing for new product approvals from multiple sites

Develop entire value chain: Dr Reddy's MD tells pharma companies

US-China trade war is going to give us a window of opportunity to expand our industry, says G V Prasad